Corcept Therapeutics (NASDAQ:CORT) Lowered to “Strong Sell” Rating by Zacks Research

Zacks Research downgraded shares of Corcept Therapeutics (NASDAQ:CORT) from a hold rating to a strong sell rating in a research report sent to investors on Tuesday morning,Zacks.com reports.

CORT has been the subject of a number of other research reports. Weiss Ratings restated a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. UBS Group initiated coverage on shares of Corcept Therapeutics in a research report on Tuesday, December 16th. They set a “neutral” rating and a $95.00 target price for the company. Wolfe Research lowered shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price target for the company. in a research note on Wednesday, December 31st. Canaccord Genuity Group dropped their price objective on Corcept Therapeutics from $140.00 to $99.00 and set a “buy” rating on the stock in a research note on Friday, January 2nd. Finally, Truist Financial set a $50.00 price objective on Corcept Therapeutics in a report on Wednesday, December 31st. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $80.83.

Corcept Therapeutics Stock Down 3.7%

Shares of CORT traded down $1.39 during trading hours on Tuesday, reaching $35.66. 124,443 shares of the stock traded hands, compared to its average volume of 2,493,567. Corcept Therapeutics has a 52 week low of $32.99 and a 52 week high of $117.33. The company has a market cap of $3.75 billion, a price-to-earnings ratio of 40.68 and a beta of 0.23. The stock has a fifty day simple moving average of $70.63 and a 200 day simple moving average of $72.75. The company has a current ratio of 3.14, a quick ratio of 3.07 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.02). The firm had revenue of $207.64 million during the quarter, compared to analysts’ expectations of $223.78 million. Corcept Therapeutics had a net margin of 14.19% and a return on equity of 15.99%. The company’s quarterly revenue was up 13.8% on a year-over-year basis. During the same quarter last year, the business posted $0.41 EPS. On average, equities analysts forecast that Corcept Therapeutics will post 1.36 EPS for the current year.

Insider Activity

In related news, CEO Joseph K. Belanoff sold 40,000 shares of Corcept Therapeutics stock in a transaction on Monday, December 1st. The stock was sold at an average price of $79.77, for a total transaction of $3,190,800.00. Following the completion of the sale, the chief executive officer owned 2,701,370 shares of the company’s stock, valued at approximately $215,488,284.90. This trade represents a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Joseph Douglas Lyon sold 5,000 shares of the business’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $79.53, for a total value of $397,650.00. Following the transaction, the insider owned 10,277 shares of the company’s stock, valued at approximately $817,329.81. The trade was a 32.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 194,500 shares of company stock worth $14,186,410. Insiders own 20.80% of the company’s stock.

Hedge Funds Weigh In On Corcept Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Hennion & Walsh Asset Management Inc. raised its position in shares of Corcept Therapeutics by 1.1% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 56,946 shares of the biotechnology company’s stock valued at $1,982,000 after buying an additional 605 shares in the last quarter. Ausbil Investment Management Ltd increased its stake in Corcept Therapeutics by 82.6% in the fourth quarter. Ausbil Investment Management Ltd now owns 10,235 shares of the biotechnology company’s stock valued at $356,000 after acquiring an additional 4,629 shares during the last quarter. SG Americas Securities LLC raised its position in Corcept Therapeutics by 49.3% during the fourth quarter. SG Americas Securities LLC now owns 13,828 shares of the biotechnology company’s stock valued at $481,000 after purchasing an additional 4,565 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in Corcept Therapeutics by 3.9% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 21,552 shares of the biotechnology company’s stock worth $771,000 after purchasing an additional 803 shares during the last quarter. Finally, Swiss Life Asset Management Ltd purchased a new position in shares of Corcept Therapeutics in the 3rd quarter worth about $376,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics News Roundup

Here are the key news stories impacting Corcept Therapeutics this week:

• Neutral Sentiment: Media comparison notes Corcept and Amicus delivered contrasting Q3 2025 results, highlighting profitability differences among rare‑disease biotechs — useful context for investors assessing relative fundamentals. One Rare Disease Biotech Posts 97% Margins …
• Negative Sentiment: Zacks Research downgraded CORT from a “hold” to a “strong sell,” signaling fresh sell‑side skepticism that can pressure the stock and reduce demand from discretionary buyers. Zacks.com
• Negative Sentiment: An analyst price target was cut ~28.5% to $92.82, which can anchor lower expectations for the stock and weigh on sentiment (article notes the reduced target). Price target decreased
• Negative Sentiment: Multiple shareholder‑rights firms and plaintiff firms have opened investigations or solicited clients after Corcept disclosed an FDA Complete Response Letter for relacorilant and a prior sharp share decline — this raises the risk of lawsuits, potential liabilities, and continued negative headlines. Representative notices: PR Newswire (Schall Law Firm), BusinessWire / DJS, Hagens Berman (highlights 50% post‑CRL drop), GlobeNewsWire (Holzer & Holzer), and Newsfile items (Levi & Korsinsky, Block & Leviton). Schall Law Firm investigation DJS Law Group Hagens Berman

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.